0001104659-23-116280.txt : 20231109 0001104659-23-116280.hdr.sgml : 20231109 20231109161056 ACCESSION NUMBER: 0001104659-23-116280 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Barinthus Biotherapeutics plc. CENTRAL INDEX KEY: 0001828185 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40367 FILM NUMBER: 231392496 BUSINESS ADDRESS: STREET 1: UNIT 6-10, ZEUS BUILDING STREET 2: RUTHERFORD AVENUE, HARWELL CITY: DIDCOT STATE: X0 ZIP: OX11 0DF BUSINESS PHONE: 44 (0) 1865 818808 MAIL ADDRESS: STREET 1: UNIT 6-10, ZEUS BUILDING STREET 2: RUTHERFORD AVENUE, HARWELL CITY: DIDCOT STATE: X0 ZIP: OX11 0DF FORMER COMPANY: FORMER CONFORMED NAME: Vaccitech plc DATE OF NAME CHANGE: 20210407 FORMER COMPANY: FORMER CONFORMED NAME: Vaccitech Ltd DATE OF NAME CHANGE: 20201014 8-K 1 tm2330270d1_8k.htm FORM 8-K
false 0001828185 00-0000000 0001828185 2023-11-09 2023-11-09 0001828185 BRNS:AmericanDepositarySharesMember 2023-11-09 2023-11-09 0001828185 us-gaap:CommonStockMember 2023-11-09 2023-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 9, 2023

 

BARINTHUS BIOTHERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

 

England and Wales 001-40367 Not Applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

Barinthus Biotherapeutics plc

Unit 6-10, Zeus Building Rutherford Avenue,

Harwell, Didcot, OX11 0DF

United Kingdom

(Address of principal executive offices, including zip code)

 

+44 (0) 1865 818 808

(Registrant’s telephone number, including area code)

 

Not Applicable 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trade Symbol(s) Name of each exchange on which
registered
American Depositary Shares BRNS The Nasdaq Global Market
Ordinary shares, nominal value £0.000025 per share*    

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 9, 2023, Barinthus Therapeutics plc (the “Company”) provided an update on its financial information and recent corporate developments in the quarter ended September 30, 2023. The full text of the press release issued in connection with the update is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1 Press Release dated November 9, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Barinthus Biotherapeutics plc
     
Date: November 9, 2023 By: /s/ William Enright
    William Enright
    Chief Executive Officer

 

 

 

 EX-99.1 2 tm2330270d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

 

OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) – Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an overview of its progress. The Company is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious disease, autoimmunity and cancer.

 

“The third quarter of 2023 was a period of solid progress for the Company. We have since revealed the evolution of the company identity from Vaccitech to Barinthus Bio. This change reflects the evolution of our pipeline beyond vaccines, towards T cell immunotherapeutic candidates designed to guide the capabilities of T cells, to stimulate their disease-fighting capacity or to restore immune balance,” said Bill Enright, Chief Executive Officer of Barinthus Bio. “We remain focused on progressing our pipeline, particularly in HBV, for which upcoming preliminary data from both of our Phase 2 trials will be presented at The American Association for the Study of Liver Diseases – The Liver Meeting® 2023 this month.”

 

Recent Corporate Developments

 

·In November 2023, the Company announced it changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The Company’s new name takes inspiration from “Barinthus,” the mythological navigator who guided King Arthur of Britain by ship to the island of Avalon to be healed when he was wounded. The story of the legendary king being guided to a place of healing is reflective of the way the Company’s proprietary platforms and technology are designed to guide the immune system to treat infectious diseases, autoimmunity and cancer.
·On November 6, 2023, the Company held a general meeting where its shareholders approved resolutions granting the Company’s board of directors or any duly authorized committee of the board of directors an increase in the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from pre-emption rights. Pursuant to such approval, our board of directors was authorized to allot shares up to an aggregate nominal amount of £1,928, free from statutory pre-emption rights.

 

Upcoming Milestones

 

·In the fourth quarter of 2023, the Company expects to:
oAnnounce interim efficacy data from HBV003 (NCT05343481), a Phase 2b clinical trial of VTP-300, that further evaluates its potential as a component of a functional cure for chronic Hepatitis B.
oAnnounce interim efficacy data from the Phase 2a clinical trial (ACTRN12622000317796) collaboration with Arbutus of VTP-300 in combination with Arbutus’ siRNA therapeutic candidate, AB-729 for chronic hepatitis B.
oSubmit a regulatory submission application in Australia for VTP-1000, the Company’s lead SNAP-TI candidate, for the treatment of celiac disease.

 

 

 

 

 

 

Third Quarter 2023 Financial Highlights

 

·Cash position: As of September 30, 2023, the Company had cash and cash equivalents of $160.3 million, compared to $173.0 million as of June 30, 2023. The net cash used in operating activities was $11.2 million, primarily resulting from its net loss of $14.1 million adjusted by unrealised foreign exchange gains of $6.2 million, depreciation and amortization of $1.5 million, and changes in its operating assets and liabilities. Based on current research and development plans, the Company expects its cash runway to fund its operating expenses and capital expenditure requirements into the second quarter of 2025.
·Research and development expenses: Research and development expenses were $15.1 million in the third quarter of 2023 compared to $13.5 million in the second quarter of 2023, showing increased spend due to the phasing of ongoing clinical trials. VTP-300 HBV research and development expenses increased as a result of the increased trial cost and manufacturing development costs, VTP-850 Prostate cancer has also increased as a result of the increased trial costs as the trial progresses. The quarter-on-quarter R&D expense per program is outlined in the following table.

 

Three months ended  September 30,
2023		   June 30,
2023		   Change 
   $000   $000   $000 
Direct research and development expenses by program:               
VTP-200 HPV   1,288    1,837    (549)
VTP-300 HBV   4,877    3,757    1,120 
VTP-600 NSCLC1   155    79    76 
VTP-850 Prostate cancer   1,724    242    1,482 
VTP-1000/VTP-1100 Celiac/HPV Cancer   2,507    3,018    (511)
Other and earlier stage programs   1,069    701    368 
Total direct research and development expenses   11,620    9,634    1,986 
Indirect research and development expenses:               
Personnel-related (including share-based compensation)   2,711    3,388    (677)
Facility-related   368    202    166 
Other internal costs   445    319    126 
Total indirect research and development expenses   3,524    3,909    (385)
Total research and development expense   15,144    13,543    1,601 

 

1 The VTP-600 NSCLC Phase 1/2a trial is sponsored by Cancer Research UK.

 

·General and administrative expenses: General and administrative expenses were $1.0 million in the third quarter of 2023, compared to $13.1 million in the second quarter of 2023. The decrease was mainly attributable to the unrealized foreign exchange gain of $6.6 million in the third quarter of 2023, compared to an unrealized foreign exchange loss of $4.2 million in the second quarter of 2023. The remainder of the decrease was primarily attributable to a decrease in legal and professional fees of $0.5 million and decrease in share-based compensation expense.
·Net loss: For the third quarter of 2023, the Company generated a net loss attributable to its shareholders of $14.1 million, or $0.37 per share on both basic and fully diluted bases, compared to a net loss attributable to shareholders of $23.8 million, or $0.62 per share on both basic and fully diluted bases in the second quarter of 2023.

 

 

 

 

 

 

About Barinthus Bio

 

We are a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. Helping patients and their families is the guiding principle at the heart of Barinthus Bio. The company stands apart through its broad pipeline, built around four proprietary platform technologies; ChAdOx, MVA, SNAP-TI and SNAP-CI. Barinthus Bio is advancing a pipeline of five product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B viral (HBV) infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. Barinthus Bio’s proven scientific expertise, high-value portfolio and focus on product development uniquely positions the company to navigate towards delivering treatments for patients with infectious diseases, autoimmunity and cancers that have a significant impact on their lives every day. For more information, visit www.barinthusbio.com.

 

Forward Looking Statements

 

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “would,” “aim,” “forward,” “expect,” “plan,” “intend,” “believe,” “potential,” “continue,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward looking statements include express or implied statements regarding the Company’s future expectations, plans and prospects, and include, without limitation, statements regarding the timing and advancement of the Company’s programs, including the clinical trials of VTP-200, VTP-300, and VTP-850, statements regarding the timing for the potential IND application for VTP-1000, statements regarding the presentation of interim data, including with respect to VTP-300, and statements regarding the Company’s capital, including its cash runway. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: the success, cost and timing of the Company’s product development activities and planned and ongoing clinical trials, the Company’s ability to execute on its strategy, regulatory developments, approval of the Company’s product candidates, the Company’s ability to fund its operations and access capital, and global economic uncertainty, including disruptions in the banking industry, the conflict in Ukraine, and the conflict in Israel and Gaza, and other risks identified in the Company’s filings with the Securities and Exchange Commission (the SEC), including its Annual Report on Form 10-K for the year ended December 31, 2022, its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

 

 

 

 

 

BARINTHUS BIOTHERAPEUTICS PLC 

CONDENSED CONSOLIDATED BALANCE SHEETS 

(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS) 

(UNAUDITED)

 

   September 30,   December 31, 
   2023   2022 
ASSETS          
Current assets:          
Cash and cash equivalents  $160,309   $194,385 
Accounts receivable   —    323 
Accounts receivable - related parties   —    5,524 
Research and development incentives receivable   4,172    4,541 
Prepaid expenses and other current assets   6,584    8,268 
Total current assets   171,065    213,041 
Goodwill   12,209    12,209 
Property and equipment, net   12,269    7,957 
Intangible assets, net   25,898    28,269 
Right of use assets, net   7,474    7,753 
Other assets   1,055    976 
Total assets  $229,970   $270,205 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
           
Current liabilities:          
Accounts payable  $5,145   $3,748 
Accrued expenses and other current liabilities   11,923    8,061 
Operating lease liability - current   1,501    433 
Total current liabilities   18,569    12,242 
Non-Current liabilities:          
Operating lease liability   11,202    8,340 
Contingent consideration   1,797    1,711 
Deferred tax liability, net   1,521    3,746 
Other non-current liabilities   1,278    965 
Total liabilities  $34,367   $27,004 
Commitments and contingencies (Note 14)          
Shareholders’ equity:          
Ordinary shares, £0.000025 nominal value; 38,546,594 shares authorized, issued and outstanding (December 31, 2022:          
authorized, issued and outstanding: 37,683,531)   1    1 
Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2022: authorized,          
issued and outstanding: 63,443)   86    86 
Deferred B shares, £0.01 nominal value; nil shares authorized, issued and outstanding (December 31, 2022:authorized,          
issued and outstanding: 570,987)   —    8 
Deferred C shares, £0.000007 nominal value, nil shares authorized, issued and outstanding (December 31, 2022:          
authorized, issued and outstanding: 27,828,231)   —    01
Additional paid-in capital   385,707    379,504 
Accumulated deficit   (159,297)   (103,243)
Accumulated other comprehensive loss – foreign currency translation adjustments   (31,099)   (33,460)
Total shareholders’ equity attributable to Barinthus Biotherapeutics plc shareholders   195,398    242,896 
Noncontrolling interest   205    305 
Total shareholders’ equity  $195,603   $243,201 
           
Total liabilities and shareholders’ equity  $229,970   $270,205 

 

1 indicates amount less than thousand.

 

 

 

 

 

BARINTHUS BIOTHERAPEUTICS PLC 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 

(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS) 

(UNAUDITED)

 

   Three months ended   Nine months ended 
   September 30, 2023   September 30, 2022   September 30, 2023   September 30, 2022 
License revenue (1)  $—   $6,165   $802   $38,237 
Research grants and contracts   —    —    —    9 
Total revenue   —    6,165    802    38,246 
Operating expenses                    
Research and development   15,144    9,744    38,501    30,165 
General and administrative   961    (10,815)   26,227    (12,971)
Total operating expenses   16,105    (1,071)   64,728    17,194 
(Loss)/income from operations   (16,105)   7,236    (63,926)   21,052 
Other income (expense):                    
Interest income   196    1,024    2,306    1,776 
Interest expense   (7)   11    (21)   3 
Research and development incentives   1,205    (724)   2,921    1,150 
Other income   (2)   —    308    51 
Total other income (expense)   1,392    311    5,514    2,980 
(Loss)/profit before income tax   (14,713)   7,547    (58,412)   24,032 
Tax benefit   603    674    2,255    2,452 
Net (loss)/income   (14110)   8,221    (56,157)   26,484 
Net loss attributable to noncontrolling interest   38    21    103    47 
Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders   (14,072)   8,242    (56,054)   26,531 
                     
Weighted-average ordinary shares outstanding, basic   38,533,833    37,247,123    38,320,208    37,213,787 
Weighted-average ordinary shares outstanding, diluted   38,533,833    38,156,564    38,320,208    38,226,092 
Net (loss)/income per share attributable to ordinary shareholders, basic  $(0.37)  $0.22   $(1.46)  $0.71 
Net (loss)/income per share attributable to ordinary shareholders, diluted  $(0.37)  $0.22   $(1.46)  $0.69 
                     
Net (loss)/income  $(14,110)  $8,221   $(56,157)  $26,484 
Other comprehensive gain/(loss) – foreign currency translation adjustments   (7,820)   (19,940)   2,364    (42,730)
Comprehensive loss   (21,930)   (11,719)   (53,793)   (16,246)
Comprehensive loss attributable to noncontrolling interest   48    51    100    122 
Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders  $(21,882)  $(11,668)  $(53,693)  $(16,124)

 

1  Includes license revenue from related parties for the three and nine month periods ended September 30, 2023 of $Nil million and $0.8 million, respectively and for the three and nine month periods ended September 30, 2022 of $6.2 million and $38.2 million, respectively.

 

 

 

 

 

 

IR contacts:

Christopher M. Calabrese 

Managing Director 

LifeSci Advisors

+1 917-680-5608

ccalabrese@lifesciadvisors.com

 

Kevin Gardner

Managing Director

LifeSci Advisors

+1 617-283-2856

kgardner@lifesciadvisors.com

 

Media contact:

Audra Friis

Sam Brown, Inc.

+1 917-519-9577

audrafriis@sambrown.com

 

Company contact:

Jonothan Blackbourn

IR & PR Manager

Barinthus Bio

ir@barinthusbio.com

 

 

 

 EX-101.SCH 3 brns-20231109.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 brns-20231109_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 brns-20231109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] American Depositary Shares[Member] Common Stock [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares EX-101.PRE 6 brns-20231109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2330270d1_ex99-1img001.jpg GRAPHIC begin 644 tm2330270d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 09, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2023
Entity File Number 001-40367
Entity Registrant Name BARINTHUS BIOTHERAPEUTICS PLC
Entity Central Index Key 0001828185
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Barinthus Biotherapeutics plc
Entity Address, Address Line Two Unit 6-10
Entity Address, Address Line Three Zeus Building Rutherford Avenue
Entity Address, City or Town Harwell, Didcot
Entity Address, Country GB
Entity Address, Postal Zip Code OX11 0DF
City Area Code +44 (0)
Local Phone Number 1865 818 808
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
American Depositary Shares[Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares
Trading Symbol BRNS
Security Exchange Name NASDAQ
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.000025 per share*
XML 9 tm2330270d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001828185 2023-11-09 2023-11-09 0001828185 BRNS:AmericanDepositarySharesMember 2023-11-09 2023-11-09 0001828185 us-gaap:CommonStockMember 2023-11-09 2023-11-09 iso4217:USD shares iso4217:USD shares false 0001828185 00-0000000 8-K 2023-11-09 BARINTHUS BIOTHERAPEUTICS PLC X0 001-40367 Barinthus Biotherapeutics plc Unit 6-10 Zeus Building Rutherford Avenue Harwell, Didcot OX11 0DF GB +44 (0) 1865 818 808 false false false false American Depositary Shares BRNS NASDAQ Ordinary shares, nominal value £0.000025 per share* true false 00-0000000 EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 25 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vaccitech.co.uk/role/Cover Cover Cover 1 false false All Reports Book All Reports brns-20231109.xsd brns-20231109_def.xml brns-20231109_lab.xml brns-20231109_pre.xml tm2330270d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2330270d1_8k.htm": { "nsprefix": "BRNS", "nsuri": "http://vaccitech.co.uk/20231109", "dts": { "schema": { "local": [ "brns-20231109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "brns-20231109_def.xml" ] }, "labelLink": { "local": [ "brns-20231109_lab.xml" ] }, "presentationLink": { "local": [ "brns-20231109_pre.xml" ] }, "inline": { "local": [ "tm2330270d1_8k.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://vaccitech.co.uk/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330270d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330270d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "BRNS_AmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://vaccitech.co.uk/20231109", "localname": "AmericanDepositarySharesMember", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "American Depositary Shares[Member]", "documentation": "American Depositary Shares" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-23-116280-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-116280-xbrl.zip M4$L#!!0 ( %N!:5?U8Y4OMP, /<- 1 8G)NM7SN^P:3=N-!.FDQ:IB3=0)OM]J4CRP(TL26O) ?2 M7]\C^1+ 0(!M_"2?\WWG(AT=G=Z[19:B>RH5$[SOA%[@(,J)2!B?]IVO8_=L M?#X8..C=VS]>(/AZ?[HNNF0T32)T(8@[X!/Q!EWCC$;H ^548BWD&W2+T\)( MQ"5+J43G(LM3JBDH2D\1.O$Z08Q<=P^[MY0G0GX=#1J[,ZUS%?G^?#[WN+C' M_DW_P MIR&+/R<_OX]>9O_>+73V/HQOTEGI[[5UM 6^# O"=;@TLE#O%.&_ $ZQB:[12K("5U&T@"-=!KG[(J=H(+54KA$3+-<+* MKH':-VK#Z;A!U^V&-?/]Z'K70F87 M=(*+%++XK\ IFS":.$AC.:7:5*C*,:%/&ZPK'7,NX$+ K:PD1I;G#"J^$8#( M5$@D14J_0!;(+.!&;O5B]/ZY@,;B();TG7*Y9*^VF- )X\QZKRYAB%QSY0J3 M+"PML^>O@]N6"D63S_RM7>>2*J#;K(8@J/@59#>7X)04Z5'4Q_AV,2MYO9>M M3:[OXHA.D+W#D2F3*K8_T!Z3M04W5$.-AQQVV9[2^ M4Y7CV@26I&6EU6/ B,BIU RNQ%(C*4-GVM#_7G*#C!_E(/\W9I[B^-#,@4+3 M9TQY:.P_1ZY098?FNEJ8SY3P1>.DG77/7VTI\+_>=GJ0N) :\58+V_7\E _G M4!!K:@?%_+DUSS4B-^Q %_86*GF,]) @'K?AL"!JWA%!;'D$-_E7V^!F88MI M7Z=;'M.=3C=R?)IJ54N.#F'YZ?T?,5@S!P7Q]'N^+9RGF/9?'54$1!1.#7_[]SW\$^M^' M[X;#X(9@&IT%5SP<3MF"_QQ\1C$^"W[%# NDN/@Y^()H8J[P&T*Q""8\7E.L ML/XBJ_@L.#DX.IP'PV&/7EX.&']&+UP\R8.0 MQ_T*G"FD$KDK[7!SF/_+W#]0PI[.S(\YDCC0?#%YMI'D?&#JS:M].3[@8CDZ M.CP,L7.$8#0DSO(5X4'B94FQ^X]/3TU'Z;6':L-S,!2WJ.!X5<'8E MZV\CM7,H&Y^,LB_+IJ2EZ!)H2 MCP\V,AH4.J5D"T[Q/5X$YG\M]*[69Q2&1.%PI<4]2)Y&YOO1A.OFJ\&FGBN! M%^>#N6!25W!T/!X?GIKB_U4Q4MNU;L:2F%8X"$:5JI$(B]IMQN5:@$ +ODV$ M)VGE*UV$"),Y'D8DQLRT^$&05U0.;U<*86JD34>YS\&MNKX_5D3I?@A3A_?'Q;BZV!=:X>.T3>(%2JCZZD99 MN%6<3 T U&BX2C],;/, MD118* \K *CIA;EH,B>+D"4.#Y;\>11A,C+]G_F0=H09=Y@\%G6: 5#$* \4 M3Q6.95$P17-,T^H>M4N[Q^C_QKQ /:YK6IMLX7IH/!;*% MX'%/0G/R>&L<988UG$' 182%GK\=OB*B7.+H?*!$8@G5#SKD%H7JYU]0"(H5HM:WTJ7,L2K?'"&!+'9OJD2S7E"EPP@ MP[P3.23%T:&?6CR.+<#?2HYBA-RWCWLSO=+H(,F.OU:R9G9P>?]Y]G@18T%" MQ*[PFDNBD-C.5DA@^2F?$39$,5[M3N^@3G66"C#?TO+Y7MC!GNO;=5T\CCE+ M(P.%*5BHFS[:[O*_A1RMB,$^ZTU$Z#]E?- EMD\1C<7C]XY)WG-&98,+,?PF M@T(WP?I&9)$!=$/1TLYPQ<0#BIMXWW42M ?'5UB&@JQ5:<('4%VR](GQ.FRP M^W#;>]SC)9%*I''L9@;MW8G5Q0,INO&#*_=TO\?Q(D%!9TVX?[FK%']-N00PJ<.)[,"*2S'!-('PGJUAYI8(4.B?"# M6Q%F*TRI60U$K->=T+3W2 @ /"3%C]].BNMG,XW0XU5_-78NG@I2Q0]I\I-; M3>YT?LXC/7,0/=2H&7ND@PTYI,#IMU#@FD5]^<]-O6._C+MM<<$E^3=$AHAF M^&[TM8[UJ8:Y1R+8L;_OT[=]A?@3(]%;AIVQ=R)4D8,2.,J>)XD0%6BM?1%D M[8$(K=!!%1SER]=,$;4UF]<^)\ S9VU6M_* =2MDD&U'27(&JGAXPI39I=?& M>-72&]8ML$'F'27'&;")CD0@.F41WOR&MVW4UTR]X=Z&&R3?45*<(;L3)#8K M<23L[FKJMM[0;P4.\N\H$\Z@/:#---+QD 7)MKQVRP"X>*-&&WY0%$>I<(9P MRD(NUKST)'W"$WT';R<\:AT:6AV]$:@["E F1_ERAO,BB@26,O_/Q#5N$\=B M[HTD$'9PLM6W G^3+)31ETZU#Q\$\,&'U3$:8I= MM)9L,M'GCL@L?5.@#!MDWFF*G0.[XU(A^C^R[IK'VNQ]4Z$)'M3"4<:=MPOS M( ;:#%8Q\8#Q)EZ09$=IM1F++@1&ND M(-VH9PX7B]O% NK!87L/-.@ #VKA*$6MP9M*F6"QKR(-+_]TL8< JN,H79WA M,-%=YW9\-'\PI^B!OJEFY0'[5L@@VXY2U,_\02#S J#9-IYS"A]*LAAZP#F$ M&J3=439:064GO&+B =5-O"#)CK+1XH:[WH0KQ)88WEMBL_2 2](^MI. MX#ZQFGHC@@TW2+[3Q=E\0_QN1,O>4MJF@=W#&RE:X(.*.%VTG3*%!0H5><97 M2*$<;YLB=@]O%&F!#RKB=+-T>M-.]'"VY.W[%RJ&WO#?1 W2[G2/]"Q&E%XF M4@<@6WNDBJ$WM#=1@[0[W05]'6.QU!WCKX*_J%5^<+F-?JN#-S+ Z$$YG.YV MOMZ\OEHA.[G9JD7#VA\A[- A%4X<'Q.^"$.SZ26;,; ("4 'V-X#)3K @UHX M2K%OU0J+\LPMA6:":=N2TN7E@2Z]0@#5<9IBEU]WT3IHE^P\4 #7+N-(.^ M2^:4A#>4H]8\H63F#>-US"#A3K/F2\2>1+)6X?9.\!!CL_PD=_=GCY2M5P'> MB-0_&E ^MT>/7U^ FKV+]C91Z9^>T6A;'WVT^'DC5F<0H$:.7]LE7P\DXNAR M>X\76)@-) ]XHRYU14_M$[!.=P\4VR\64+A2VOYA5 M35_^DO\NOFQ_F[^;H M*W\!4$L#!!0 ( %N!:5=EU,KM!PP #>1 5 8G)N&ULS9U=;]LX%H;O%]C_P/'>[ )U'">8!9)I9Y"DR2"8-,G&;F=W MBT5!2[0C1"8#2DZ@_U4GQ,4K)X]/Z7[3I%3X1G M":,?1M.]_1$B-&)Q0E7E"&4YIC%.&24?1I2-?OGYKW]!XL_[ M'\9C=)&0-#Y&'UDTOJ1+]A.ZQFMRC'XEE'"<,_X3^H+3C=S"+I*4<'3&UH\I MR8G8H0]\C'[<.]A?H/%X0+E?"(T9_WQW695[G^>/V?%D\OS\O$?9$WYF_"'; MB]AZ6(&S'.>;K"IM?[M?_-'A[].$/AS+OQ8X(TB<+YH=;[/DPT@>MSCL\^$> MXZO)P?[^=/+O3U>SZ)ZL\3BA\KQ%9%1&R5)L<=.CHZ.)VEM*6\KM@J?E,0XG MI9VJ9+$WZ=#7G&3)<:;L7;$(YZK9>P^#0(7\W[B4C>6F\?1@?#C=VV;QJ#SY MZ@QREI([LD2JFL?YRZ- *4LD":-BVSTG2[N9E/.)C)]0LL(YB>6!CN2!IO^4 M!_I;L?D*+T@Z0E(I^ #K==0HJPB:N#9[2WC"XG/Z-M=FM"?[XKO#\^^H0#W> M>17F+,?IF\S7(YW;OB9O.^.[./=G6O3SY&UGNA;YI]C.VY9??7KMYS65&Z_$ MIX9%LLW% $;BTJ0LHJ,'5D=0 T-1=E4ZBQKEIK(W9[Q==SDRJC*7.%NH@C?9 M>(7QHSC P>&$I'E6;AG++>HD%!N^R;&1K G-SU*<93?+6PQ'Z?ZI.OP)6?K03:*<\8&B+^EBZI\ M?9*%!: B#1DG&=OPB+RJC>NU&7I6"X?K5$3("1NAX\^ST<]*AM@2*2'Z*J7_ M>S_9%?T6EA:<9@J0Z73_2$%R>G<]^W:R%AUYA.E'\LBR1'3G+[-[+$[ )[)> M$&Y4:%"$"U!>85VB,D#N'9;A'DU[ MAJ1NRH1"[@L*@IHAL-&EQG$#B[D.C>7!+U*\LM@W]KMJ8JNMLHT;.X-H9)LC MRZQ2:Y 4^6KFCR2+>/(H^Y6N>C1DSAO=8K+5]C5-6 BTC<$DU+2>.O8[LDJR MG*N!IIJQ='1C@-YUU]]IVQP+K.(@H!GB$!PMZD&HBO+$T0FE&YS>B0MFWH5/ M4^::&IM)$Y:Z)BA&+,9 -+06:;$G(OZUP3PG/'WIA:*E=,T%8-5$PY %18?= M&PA()??+R)QCFB6R ^N%I"UU?KD!F&U=>ABZH#@!S,&7))7>+RFS>Y*F\D$) M3/L[%)O8-2VP89.7MC(H8D![(#,J A4AX6!S_B1GYV*:-+"R-;U/>%JVN_BI MQ,$B9#H<2)$*0S+.$TFUYS-Z&&HI7=,#6#6Y,61!$6/W!K*BY4CI_4-R3N-! MB%0Z/X 8-NUX%*( X6@ZZT-#J'V"<9%D$4ZUEPNQK>L7&(O6-2"@71.2EC H M4"!W("PZH&1&A7@%YC\$\V&XU)1^8&E9M:-2R0($Q?36AXG4>X'D;,-YPS4\ MXL!25YCTF2TY@71!@-)CKO5 B)8W0/$T IW3/,E?Y$*#ZXWE02&[Q!4;D+F2 M"7-_$"P IDP&M Q)'=)"+RU?_DI <[FZ ZR.*7-+@-UDDX*F)B 2K,8 &G9: MM=C&"Q%GHF?B.+VD,=G^1E[ >K5T;ID ;#:A,$0!46%W!F!1B)%2(R'W L8M M3];R"=DDZADJVD*W:$!&FVR8JH#@ *P!=!1J-+L\\SF2S/'V,A:@)LM$+Y3K MH034NX6EQW:3&4 <$#K=#@&"1!!J1OD$Z9)&C#^RVN,.9VPC.L"7,Q;#,Y2> M*+=0#:I"$ZW.D( &^(3P*P1^DX_DX*87."L"D"R!"_$G<2Q.%%9\<]50LD4 MK+]5ZY:N#KM-IBS"@$B"W0'\%,IWY0^H?F<"@TAT%#<_@F:$3#>^UKSL3'&SYGS[:'LT&E%V3: M5JW [&3AX=+RU@>+#)#S&1GB$Q,UL;KAMYP])32"I\R0W LP@&DK-88V/'3L M!OOXJ2;$99S7OD9/RGN_)*7,3R_3-&GO8K0F/$B:QGH[%ZWVB<0MRW*<_C=Y M[+P0MXN]X&$U;(6DH0P/%9N]/F!T#!)!/BZL"USE#QK6I63&?F>_-MML53\Q MUW<& 8'-43N[@+Y[HD6NFUDRR@D&>H3F;F>-;#%5M7%M7QA-W#;4:F'UO18: M'U]DF?8NO;UG%'Y H"UQU=*0N;*US?U!M#A@RFQU)4-*Y^ENO$R]E=F[[]H^ M9R.[::<:R,L=0;2NZ:8U3)?[';?F[SS)Q9%E+IH-+7[EL3TW".AS2YR-28"Y:D0R]@?!!F#*9$'MD\E0IP=_7_P#E5&.F_^:S3F6 M6?5G+^L%2X'L4U:5*P@Z+)8<6"1!H #[,FFX9JB0(JWUD9VJ8=92'6._*P"L MMLJF;^P,HM%MCEI?_D9;>^KRS[?1O3!%@ 4)=IGKKM]FTNS^ZYH@$.@PUKHH M*:2HU/I8D+ ;LE;]DX"5MTG JF<2L IQ$K :.@E8>9L$E(?5*4)$OW2S2),5 M!I(3=JI=0]%AV>3#(@T*%=@?V&=4(6@7XSJCI4IQ5DN3>R$^6&H)Z)SEM.RR M626UM(F"8*3+62NMI4XZ5\]<+-6NN=C$24YB;>8BH9A&"4ZK](BV.^+](V\V'9@!Q$#@-<0@\.B.#Q@\R"I5AQ9TP+R1]8>F&RK>+J-< MVGHF0.>6',!FDQA#%! I=F< (948:;6?!=HZ>T0UR=(O9 0K",D=+]?N-&VL MVK9J V*FTR"TAKO(^;&;&^LH3TLL<\)QE"=/Y"/.<>$-K"\D=[VHLLNTN9K2 MI@T(H4Z#X/K)*D:FBL$E4]Y2QO S,=5:L8ZGQ V5^\0Q+8OMW#&5)" \;+XZ M,LAP5&J]L#!;XS0]W60))1D\$!DJMRQ8+399:$@"8L'F"V!!25&I]<+"^9KP ME1C>?N7L.;\O\K."=0/4;MGHM-QDQ"H-B)4N?P S90C2,65*73_P;'<)Q766 M1;BF%JEC;$"S!C,M74C 0.9:M*0DDO=;KEF.Y@Q]S@C*[PDZ+][/6\\$K\OQ M]::1*)(+(O2LG,:8VQ#J$CM_ZPAHN/7ND98R")!Z[<'O(:DB4!GBF)H;P3"O M7\N!JA_X05P0--5]RU*FG_4TP?^.8QCUYN.8L(D4]9955OU7?_;6"T6V9>5:4F M38-" ^+L-7X! G=%H%H9[VHCEL^;>;4WF>LWV=]L\DR.H,(8?!>\,\CQSPL# M*F#\R- 1$1!Z VQ"/SC4WCK_#NE@5(OV='V6[;( DOCTY8XL"9?K#N9DFY^* M SUT7&$,B'5]]3:X.N;%7&]@$!"^UBUTJ9>A>@%H(9\1*XI 7V4A2)72^?[R M/Z$E3^^N9_+5O#R),/THNN(LD;_NZB_+)V)>1 V0?XM9Y*S5XN+LVAZ)'.[5 M\OYA%81V447W86F=^J8K\4EL+C>)OQ8X(V++'U!+ P04 " !;@6E7[7= M=4,( !.9 %0 &)R;G,M,C R,S$Q,#E?<')E+GAM;-5=75/C-A1][TS_ M@YL^AR30+UCH#@38R2P+E+"[;5\8Q582#;*4D61(_GTE.PY);,F7_8C4?6"# MGO=5H19S!/")B>MC\/VZ; _&+0BJ1!+ M$.4,G[08;[W]\\]_>XH:K]4J9D\ MZG2>GY_W&']"SUP\RKV8I[ *APJI3*YJZ\Z[RW]%\6-*V..1^3%"$D=:+R:/ MYI*Y^\/5\-XBE/4)LSH%N-66N=WAXV,F_ M+:$5Y'PD:-G&0:<,9U6S_I8X\&N12'(D\_"N>(Q4;GMC,Y$587YKE["V.=3N M[;GMSF;1*\7,%!:?X#H\C\[]V;]7J$XICHG \U8[M98\=\WVGSW6?U,'F M):<"CT]:(\&D;F#_H-?K'IKJ?]X J<5,]TU)3-=J19V-IF<"2\Q4SO9*']@H M@N=*]RBU3?_*4MV<_E@@E[&4T5 >;P1 C0]\BVW9 MIW.U)8[W)ORIDV#2,0J8#[D4N0SZEX>\H=.15 +%JJR)HA&F>?T/&K,%Z7QU M5&,D1WE'R&1[@M"L" U3)[1R/A4"70)W,9M1[ONZ*G8 MC!R)N*Q8?]RPL]I_EXC.# E=7SN>$KKJ"6/!4YM\RP:Y,VHN$BSTJ-KM?@N] MFWM!V?/,Z";2LKOC@0Y*UG<*=PG/JEM4W92^D<32A/UO8\)7=?H^15+>C(>* MQX^GJ\?'9W/7PX3;$@,6+G>,8E44@LAE/-2'[ Z>AE]ES3VI1J*M0D^NI<_TYR MVSM-J3.$1:5K>#H#>)IREG.QFE+RKD*!5ASXL\(>^W

0/I;>3^"KEKJ'H:,^[PA)C,PX2RFO+=@XBEB+=A^\N'%2=Y3X:<,I8A>J-'@PR82*/\O S.G:( M_E4TT(#? C+ 1MF3 \,IIM3Q5_@N60,5?0<%I6'#: M;['UI/PED3&B1427^EC#??X:.-2!$#+A1M9>7?@'(P'V8 T,=2"$Y+B!\8[U M[V="; 3C'(+L:*@#(:3%39QW;,$%4T0MS,*.Z\QR$UG#JBBHY"&DPC:.7J0N M;X1D(E#R$#=G'U(GM?QRX0'; $S]_CA4OW"A0J? B9KY.M%^5O M!4G-,S02-X\P52Q4^Q#R73=?+^+?H_D@T0S(F!2KQ9H]L!:!6A%"L@MB[\61 M 8NYF/&U^^%]GNFS=='GB7,Z:"@(=2>$+/@52GCQZ#1)M'IR^9]ATG,Y4PL' M/S$+Q@\'ZT!M<.("[$$*&W,C:IPM]_?%&W/-G MR\-[*QCJ0 @9<@-CG_KGL]2-N!7\B13+\9M,J)2 .A%.XNSF[O5T**X7(.=" MB83*'TX27<_5I^RW7"I$_R6SIDO6>CS4@G#2:1?O7=\R+;J!N;-B6\&U!8'* M'4(&7/$VM?@984!B%MAM6-5/PNB= 1F77K&EO>5+(\,+5"HVB$DI4ZV M.U9^R"F)B2)L\D%?B@J":+WL=3BHYB&DH':>.Q;\5F!C/-:7^_EJ.K/15MR, MQ[91VX6'&A!"!MK,VZ\1 RDS+%YK1TTIJ"DA)*-0#78]*.$XTV/DHK<_NC=[ MR2U#4@4%E3Z$1-3&<<=27_-[@ AIIX/ICC7?B*-> M[2T(5.<0\LU:=IX&D(MY/$5L@NW+0NJ14+U#R#]=7+V-VQ/0N#UYY;@=0AYJ MX^A)ZF+MOS[?;D:43)!]#Z*S '@/5D &.)CO>B-HOAUL+?Q+_:'>!0L4JG\( MV:N3[:Z5SQ*B<%*$=$D88K'.[%8[(BVW$)I+0?T((;.%:N#EZ<9G3.E[QI_9 M$"/)&4Z*%,/U@,-:!&I*"-DNB+T71SYQFC'S H[\Q7.6,\0"A3H00FKK9.MG MN6RQ2GTU;Q4OV7,98"L!]2&$/!?"W=.B087-B\O($SY'"BTC=-EA*P&U(X0L M&,+=VW8)T=>3UH2[5Q]L :'BAY :.YAZT7R8(DK/,JE#ELZ!: L(U3R$]-C! MU(OF%RD6$ST"OA/\64V7>X9=VEL*0#T((6<&,/?CQ?SE90;%SDFG$35H\ LT MPG'!RMG7>V/BV*Q0*2X*6(*$Q007'FI#"/ES,^\=&W&CIEBL7YGEP9CP7:M) MFDM!30DAB89JX&>:7GN[A'.6WL!!Y0\G7:[CZ6=[73:B)+ZD'#GS@0T85.YP M)%J\ MT/4F4_D?1M#Q.>]L.,M!G0HGH8;HX.GZ2K[L"<3)V>(.C[$P"S[N\5R=Z88> MW9=;@.)0NT)(P5^M2HUKQYT*3=WDH_YV^8WY8?[X@S[R'U!+ P04 " !; M@6E7Z:__L.T4 !=< $@ '1M,C,S,#(W,&0Q7SAK+FAT;>T=:U/BRO*[ M5?Z'N=PZM]R[\@@@("JWD(>R*KB J\4FK/. VKW>4>O(005GEF& MQNS(WKPEU%UQK+@S-9D=30HT)[$9QZ3CJ4Q +++AZHXUC>;5:PRALBUGF2AX M&.ITV&YV9KUNJ2RK#I-'"=E(N#>\HR2E=F/<,AE5X"?!/_N.ZFBLM)\4/Z%U MS!Q*$$R<_7+5VX-8Q= =ICOQ+G 3([+X=A!SV,1)"@-.XKBD!W;_'_$XJ:M, M4XJDPYP]TJ1C5B039;)'&E7^H9=*5WH7G3_2U:-R^1Q^('DD'G_JZ$R]A]SV M%KCL^5P^ U0V-QOUDN$[NST&V@DLP/_E,=,5^.O4-3KL#:AFL^> *@1 U728 MCVD%8%E4:^@*FYRP:2\%SK"0+DB%G6? S:=[G5:O*^#^566F4U=!E^&+BE9, M"O#IA%0,=.FDR\:F1AUF__7UZU=H:+=:.+*F,>0+/L'COZJ&[.+7ACXS_E/P M"0V'C>T$X+2?05WN$!2AVI-ZGML39,*CY\ #D?48G8OW>->7@"Q^;/GP*DB M+><>K,P222N!]PUE2FQGJK&#V #LHTBDE.F0KCJ&+DUV1]K&F.K;XL$V$&"I M VZ)BGKKCU-4&R0_+1+=T!EO5"=%-"EFH:WR;ZJB,)U;+GZ%CDV8!TN5A5%. MG#;ZQ;+=&J FQR4I#@9/=. 4P#.U&-+/6(DKZ'XR!.GEP",U-E::J^PK,:G* M00QF*:WB) #0G67D73II@( <=:#*7"L!;I]92$0\)?Y$$I$,R19I@B6$61#5 M,%OTP)6J:/,0!(@C/*XHCO@RU+=T.^Y[CL3$5F)>,SK_@YBM@D$QX2(]5&'@ M IUMN):/#;IQ12MZXN"L+XC#=]]^5\8%,'LZ>ZYZ\F 6X>2SR#6]TC@)S]3B MX#FZ9"0^#YL),C6492H@L+*<*KB5TIP%']*\;6D8:.N*07[+(EDA OR'GAA7 MR[9N&>,YCOFGGNS:CC'NE;FN4!U\IV&K0.]4N(@S)M3K@^9B+EXV1*L.-'A- M"A S,345%DE!*U' ^DB$7'@FW#V"/B1.-74( MCV3P?[AT *Z+9J-;JY).M]RM=6:KW5/B/[ MMDEU/]GI[:;R?%,@'O=S;MR$ZDL(%<<1* MA?C)8K:TGT3JUNT]'I'OVK0%=+9=:W9)NW;>:G?7JR4KD9Z[ENU2W2&. 0-E MS$H%OU*&&!:1=K:4+^]$BC$@SH@A%:ZE.BH K$WD$=7!^Y5EAT"SM)O)O@,M M[S/AW)">O2D#(B96:QJT(]7>W"0)>X0+>U\>FL^NR@<6I*7M3(S:0VFRHVGBJ MX>#V8/3,I#/M1J9_KQP>:R]TLU&X(-0]'O%)F6[4)!?^ #* 56#/"";6);3(9\TJ%J"!7Q][< )<"5F&MV:LM MJ@@'ZM"^QH!430-QR/P ,A7CWTVJ*/[W9R,.A*:SB%,V-(V:-L25_B>1ZNP[ MEH_@EEF.*E/-%R%$L'XZM.\H03+\"!5HB9+ZC(),YH_7.+)%94^'E+VARX8% M'HSOE/(LOB*.GBJ&LD+WSTSEU]0]OE9.\B_U2GBN6&3*D%JF9=QZAUUAS_0$ M\F*EFC[4J*X0_'M)-4S2'C 1[Z.CO'(^LFN=C\/0?."IC-BPCA;^F'4ZS2-' M^5%07N5XYGAPHTB*9U.97/Y=I+=>;=X-26_%WG]/F9Q&BU.I*$?-_OCRI*;$ M"#_\/(@5BU?5JV)Q?ERP0"\J;UR=Q,5A 3\U"IQ'P-KID+*).UKHEV9RBY0D M_&,]SX'XG][.SW,KPZC4@#C1(C\A3+05E<>L@D2&UL:L84]VG?A_6PY9*FD0A+8&XL2;[D ME]XHW-G#Q=VPBN1NI&(P_+2MG+6)8='#%4(>KJPH%K-M[P<>N$O1GBW7O)BH MV8Z6KJJO6B@B$$*82BT54@K7)HK#J^LR,^EHZ9T> M&WFU?=S_LSY:L_32L=(%[ICGXM+2.;0GJ>VE_9_'=" 3S<6?53W/"JKKLC4S MD8F5KAG.OJMJ&&&3MHM: !&>0LJ0%KM+%04^:[B/_1%Z4(V28 4^MJRN<:=' MRT]V!X6+7./2M.1U"'".+E8ZIM8=9"C;I*HJLN&L$M0.I^ (2G&^&.S?(\V3/%-\/&R:E*-L F3 MP;W?8N8/ZS-"A2;-1=/?W+A739".PKZ\#XD?N1;[N3-:G:<&)!+G(T-_,*=L7$\ZU=M,1U'[ M+W4.BXAB):F0VR$%J4 *J<+'JO1\C^U?_RRDI?R>#5TU9B*U1.?DAO29@M"% M0K_'EOQ[G7N$T]+W-**M.KA'R"3%UJ'%O25\I<+3@.@'1!Q *,2&:6";&QJU M_8WU-]Y 7 / RHC)-_Q,A9JF98#7Q/RY;TQ(GVG&';*'C2@$@;L0/R$#5<.P M2;5!\1RF*TS9W' ,X'_L:@[5F>':VI38D G9@RD?[XTP^B!?D2!Y)SF!G5@7 M (%@]:G?-C T( ''X3Z;BHFL77P[8?Z..[$>\'36G(0+!U)8.?#2C:K%8?$! M':O:M$@N<9&'OW9LY2G$I:4ZH!.X]^#J7C9L1WONDPRS3\=2\\9]^0%1WS T M1G5>!QQTZ9%DB"DO[*WTZ.$?3]@L?+&,/?J SR"!Q P1@B=SL %@Q_6 MHJU&'_U0SJDVNDS_7+O5+-/PB4QF3ASHHZ!NA;U(61J7T@&3"14)S PFFTJ( MGE_^-IG?RF0DSV3.+88.'N\A\)H?#$6LUF"P*E7HEQUV6SZAW\?K-YW5M'PB M$P(BXW* RJW^E_$MR=9E1CPMUW]7G:5CK:KAFV[S'K4NG([UYGZ MI'Y5_?F\/?L76-<21;^_C658/+LE/\/&O 'O;V.O!QB(8$7^QRQ(G\V598;H M2_RD$.3P?YL#BI+Q"!?B$0<8$CM8P>#ARR*Z=186!H=QN J3O5/NH@BW\&)] MK-3%6@11;BB/B(RW:IYB@BO82'\8&Q95(-^:CON&MF5_>04+'S833:_BC4\$ M\YV)H>/Q,#S9[UO\6N?<#".8#-9Y/,YQM-*^ ??+>P^>7YE*Z3[7P,AURK_& M!MU77?OJ>;CV2^6#2 M\2[]/+P:/D6!5T_;LOS17F"L,)BW%_ZD\/WHXJ3Y[?A&>B?AAQ@4=TM7ROAU MPGVU3>06;,(/)%96!:_7+H;.Z8]!?7AS^K9VL525"5PN'UQ&R0"\.T0336HK M]!_:F5_K/5OK[^,_-P MJ<$+KA8_Z/I:%L@9_9VXY+A-Q/5%C=Q2S64$@[O,7BJ!99#I'6+BM6/L^.]U M.,;G3*H?9;[4)P3&OTT=6;AF[$U/]30V@.2JH2N8$3'2GQ*9GT'!D!L@@/&Z MS86C(=4FH-V@F AU2(:6<>>,-C<@LS+QO(C:1&$#B'=X!3\F51!P[9#ERT+S M.T(9LH5*!S\70$1-^E;&X$[A\MP,9L;3X\ M #WQF4\&:V%I$T_8 H^'[26;#.&:9Q_+$4=2$3BB]Q?LH[9\=%&Y'9R_^KC( ML5RV7-D220N7;#KUZ,["9YW(2.,;1)B3/\%831!IF^KBB>WFQ@@LCVF0JX/E MZ0;/W%V;\6Z E)\,$_Z&-96?^8I7"^"$<&3:%+'?J8 ;K5@'?J#%8K>J#>/ MGJDNXR8_E7E)$G;&U]LIU%)L<22L!+8-^!'TPO7$+3K;-PANI"1>K<3AZJS: MI#MC4MQ%B];@PLD/>7*4D2??GU>1]Y0=LE64/'5G[+/J;ZST[]4)#G2=DCXH M&ZJ"+H,V@,I&=-_<:#.9J:9C)T@-,^&5(+%P P##NFL3K+#9DG -"$89"8+% M**C#CL@&MDG?!=>O:U-=:&$0K-1]S0P&%[^, EQ3VLU0S!L%5Q:8*W M/#!V1KJP4W4XXA9I(>M8_18.EC8W^-TC8+G/D+C 3MS*LV9O[=S&%9>.N7UO MA_;M*+&922UT'G[A$A?%+*Y$!K&8A-3CN03 E#E50VVZ_:AHD%0V86/0B@'$ MD9P^PV36K)[$,WY8JP-V_\A5X6A6N"_QUGT:+WSJ=?JMWE@1>"-%Y!LK F^T M^ QOK%AQJO[PS:KHNNEOYEV^5C\?4G6VU1MZLQW$_JJM]E4-(!>)N$CUJ@KK M%[ST;?U^.TJ/<)+VH/\O%[TK@!4SQC.89>59^483@4DHEY3&),=[XH_(\?.6 M&0\!RH(&X[]#9@F]Q>A-O,_ )P.-)J"[*H Y_R M77@077VE) MTHE4.@$NV78UAY='MWS':?/KI_59L%4Q(/K#AL1G+UULX2VK\$W_;3*_V]-= MN-A#MG YP"):B.8K?C(#WZ2]+YL;LW 2O(AK*OP2(;\,'HA#U?F[0KG0<&'E MYWOBJA^#)/26:88YYM$#Q *(\)?+KY(3$0QW&"1^G.),2I L5O6!JVD\4.[$7@I1PA^=S3O (#^(!B$*8'8@NO-2B\(+X(J2!H8T#7P^W9S=7 M[R '(K;;_PE8Q;1A&$GYHJ,*@IP1!0\KJ,*=+TOP!DH;X&Q^$U4$Q[,7=Z+< M,.OR*G-YR"="L*?$?,;RZ?0V'B^!>F,_-N'JBT7 C,?*H*B W'O1@ARFPG8A M(*<>(9]:]7QONIM(28F SYQ%M\*9>@IG?WH/NJ5X]08^Q;_SP?KL]#RZM.-I M\"(J=F9("A@R4R)>F>N,TYE,*IU/*5*/379WXU)BY(QG'/!;]N#.+2H#9B;$ M^U!5SB-T+16GH#.;Q8#T@9*6E_'M;V9[K.^F/Q/OY^A;!+-M;WU4N'];# <2 MBQ**>F/!T(2EOD["7N+ M).QC+[AU&D?-B7?OL,4/P98#B.."7JUI>]//$F%C$F8'S/3Q'4%P(%V7J MXMX_#^C%%3K$ ^&L#0*#!B\GZS.(= <84O+T!V-7KP.$SLS580P'1UUG9%C@ M?)0WC"L_-+2)7%@BCYME ^G3#V+IV*K!JYU]T($_\OJ,IQ9)>/SM('L/G8_[ M_9[6+;O0[V$:GK@L![G'5PP6ER*-!U??%XIY6GP0ZH*_[R_Z^Y=A3=I)L-]X8@71B;Q-_64^"^K#W";%OD]V?-_76W7WY>_OBZ_=6=EJP-"-_5Z'YVJ_#BGDR/*E?G/RZ//WY MK5Z9J-W[=KIRG^HXA?:D?GQU/&V>-KZZR>1YZO1LTC!8MR&?]?.*=/C#30VH M7/UNI(ZOC[\WV[^^%0858Y@?&'6\S>5;]^=G>JU*TW+=/?;L7QWVC>'2GE G?[A*.=HP]3Q':OE M^[G1Y/Y:SIFY]H >736F_:ET_'7T8_KK^%O>-$^_?KN]GUS\Z(RGE]?FF?5- M;25_'-[O-FIVYE@Q_MR1!]8UN^J.;SH7TSO''H]3;J'%;@]UEYWK%S^/T]:U?B2K;?7!A0Q( !,K-.BYA4[5?M5U7M??ZM\_WJXO#@_%NC>@D_"?[OO-/L M7#4NSD_$3_CK2?#G\]KUY7](N_.?J\;GHYYM>:=$D4<>Z; A=4F+/I!;>ZA9 MDOA"(FWJL-X1O BOWH3O>?27E]%,UK=.B4XMCSIG9*@Y?69E/'MT2N3QKUW; M\^PA?'-T\='JNJ.S\Y.;9P9S6'_@+3'6>>VB\6O NLPCE4I6.3^I73P_<*Q0 MFK2W%)#-[U])^[8.+P_57$Y62[*A_)?^JE0R"AOV95G)_CGJ'Y'J5>?ST7(S MOQF-93D>C@F#P:,P110*SH6:YC#+&_@NJ3&;W-*1[7@NZ0R88Y#??CB^M_?[F^O93(G<4\:I#?F-4W[*%$6O9]EL@525#C^.O5=:U!6HT_VG\T M;QN?R$?+T-S!&1G3\_ ".H-J*.-J.\QW24C4R?'K6K[LOK[*:G=MMJ?)-*S MG2%US$?R0]-UF% ?X&,2\6Q#>P0"6[9OZ0 & W+W0@X0)V O$U@"O@/V?57 MP"Z[)V!$]HP<^YX9U#@\T"QBWU/GG@$=X D<$/[8AZ'<+/"; @N'(\UZ) P8 M2W2364S7S(SK:7U*NLP>#31GJ.D<%P!!#YXV!+N!2L2"\4W2 =:8)F'#H6]- MXT]T@(<9(") &H.ZP$7 R[-)WP< .1K\'4K<1]>C0_P3 @P34:(/'!O@(\>-.3" M"%ZV#?S2M4UFC!F&C#\\\"9,RY(_*!EH]T \!LB#@-Q3S43ZPC/TWC:! [:% M ^$7(>^ [I:'5.LY]G!* H'R,VH!Y0.D0A]H5A_'[IG !'=V[,,#&-SV'3)B M(PK" S)#'VW@QCT.:R$I//M!43W]8175PU-BXBSW;&4M?53)0;Z:/#64-<#0A>8P!H MP^)632+U :,]TOA%=0 7:'W=ZS%=,.T)O0+^_@' .'2H,0LXIOLNX -<"+F( M,$U33"(C$ *F Q:H$>"E;[4?7$60AP$#OO@CX!R^-7+@!?BD.; -4\3# 3K M,2 !%VX&@#I1B>> OG#) ^!Q>-"E^*:+FM,@FD?.OURW.J$L=S7]9]\!=6-D M=-NTG5.X/)! M$0"!'<+0@^#K;,#7)&L%0&]SYC0"?Z=:NVJ0>N/JZJ9Z>=EL??U\)!_QW]LW MU7KX^Q_-R\ZWST>*+/_S:%4( K=GY$4=GY$'9.C!%=V?/. M9?C$ S.\ ;R850O,.D*'^?+BF3\OE+SVX[!KFT"4(3,,VSL+Q.;I>$^]R*.+ MIH6N 1UV T=)(E-Z><:"!PI4&'-+ [/V5-%&W 6NIH(U^T27HZ6COV 2-]2^ MW$= -?-4]<[8]X^.B^L ( F"2BTG\ S9KDCY@0K&]5)H,/& (XU(\(Q?/0& MH"7ZW!>PM'O6USRT20^#0%\+SXE4'7A5:$B'>:@(NX_$'; 1HL9MOFLB)O! M]5XS86[X'O340)BOAP&UX#,WAP^HFZ@AD$'5_1C:,Y/V*>@:^.(GSMFE\._A M00 &C >&U 3/!1_'S@ C>>BT">\7 MS:6%= !.@RF9:[4.#R)^C>=04+]19\9]SIM!03SIW'+QWZ8%0]6F<0:A=<3PKB9E 'R#Y"GQ9H#*LB6 LNZ3N:Q5^: MQ[ZN#6X'7R$&8J6S]$8ORDZ=,Q#$0\LIPCQZUZ1R[D\KE\6?D$1C&,9[KCQ(2(;)"C/SHW MF9PL(U/!J/:0X$!^TIR$07+)@P1M//!8X$<=EMJTKF)BPD M4JUE2FIE1G(&J>1L2'+:?A?<-EC(X(M@#@A]"Q>_*HU&)F#$!0 87?5= M#QQ-IG%NH00 965IKN]H4LT@[5;U)M-I3K-[G'E%3QZ#<^Y?ZA1&U4-O_D57 M9@G.G)'EMWCB=VO"H?Z1R9 O#-ST4W*C]>D9//^73V&IPK DDPDVKP+,&G'W]7@RCM)U%@D"H0U@FBYR8)=XO3D]K8$8P M3,(C92#D!F[_K85[/!^4;&'R.*<='Y"G#1"V,8)(%9<&6[E@N\+-E2RI:<%N M!3C$#CK*F(34'%WPPIADI3$C9KGS0RJ7+/1U39F8>!/6RYN"PHV MCY@'JY=_:S /_7$'V>Y0G@07:1"## :4S7 M?OW$+CXHW%3\*MQX#'<$ GIF;"L3DO;VHS80"1C^QYN M51HA9WH070D>>%K7?&^7=[DU'OJ(POGD\>'(!3A;[C9!4_[P8+"#(N^YL*,((O'BCZ-CBL:> N+>97^8ZG2RANE#S5%2/- M,(!1$W]W/-(+0X=$[EQ.@5Z_1IJV/A^I3PGZ!C3F'_&9\1+.:[@#PM?_.A#< M!7J-71Q!JY14BTE5YW[16J@CMNI64PA/YEI$]C@IO"H%/\BR_$:X4HRV *.E MQ?F,1$\2.?WNL2KG)357EM1"X=/+(O\B;B+Q=\DW+!?')F.?K?L8NC&G+U!B M 3L6@1F%:4DYB)R:7NG-5TR9(I90Q-ZTM/X0A_0B: UY\B\^+WE*3YVNU\:)*"^(JGE\O((O!Z0[2!".5?:=R(<%_*5 MM]'@T[N8.;$4@]Q#)?!/%O MM>M7=7ZV6PE/=">6N(7"#HI,*:(_=P&IXGLN@E6BGB@X"]+"R26Z(I74_ X* MDYI7=Q K11=]CYPD M*Y&@; ?P.BXHR@IH;2BN6"YE/>=R!C\LR^\2:8[)X+.X\!LDR]Q54N//,VE5 M2.=S[M4; W-5H%R,>#_Q@KF+9"O)D?60$NU%[5B,Z,8X@%R+!5YQ&VP>K!T; MC_082V;KU[N]&#]V,8G+"W.%VDJ1BM'@?NW8I#R8XD%%*N8B(4[*@HTN ZE2 MCD3W:T(FF7N?36M9?9IN>::()0NQ]\H8W%#'M2V+FAF'8JT8@QPS2S=]U!KB M;G.FR\]0XIE46#O\2/6GY#)#E4HK1:5)%[*P<^*J'1 75=[)E'/Q7;=EWA;N+DJA\3O+5GCN?A]2&?E\9!\T MS?^\J*>4--/X^@2MNF*D][YA7>SY,[9TQ)>F#IY)'>2D0G2#.LW>;)8%%7E% M19BR(!X6'.?**]KOI7")(V39V,;$2_HT%:3G,K$%20 V+1_7+;^4 M!RON2!17W1%??4(./P0!SD(N.Z W>_9<]/FKM?SV6>10Q*UA,37H(0K+TIB#)G%L-(6 M+[$[6T1BB0?#,A*3$B[/5I&0HF4D(N4GYI>1$+40#!J4=,4Z+UBQ'0O#>B"2 M79]7-@CK203U6OY>5*\E*-=2G%1[60[JH)[J<\./J\GD)]5@ED%-5* WL)1$ M4"MB!ME)%9NG^&J3!V$:D_8#CHT!"P.ZW:LN*2:P5EAL2Z^O)<0Y#9&CVBW#+O!#"I5?14 B+5EY\6,\(*P@[R M/E?BM4+XPU@VB#]Y(<+U'33TUK^L5:T^\%EFR*\^]3_V]#R$]7!:QV M;=^;[:RPW@J ;Q_P#\H;"+RA\=+AP>I]=59IO/1,KX+#@V_4Y)!A 5Q>M(TW M2^!M>;AMPX)Z3)2F0BA$3QMFZ6P$*E\3K2X&X.Y[KSMSIRN#F3;V5G8>.LLXQ[+3V+MP'%C'^YW]="YA3D-7_>F.:+I#C=Z M0%<@.KA+#G?VA*&]J\!4N^#SX^P#"'LS M#G-_DH$/"P5D9@26'=8,S 1T/?YV\^/3V5297NPZ$ H>G8[GFV>N]96) -41(N0B;PF;C?O0S)QZT^'!J641S-7N,[ M0W$Z/ @O,.%<6-PQK% G'EH6R?H<),DLCD#,\=&G8+4^:5DWW?7DGH+KKN/K MK <8HJ\.KB\V7>-,PQ+K(-.V U."*R;\+-Z 1G2YXHR?3J>"I@ ? _RPL!BH M.]./#& .6LE@$Z^@6Y@!7(&%P4O,A<661>>[6HZ%<42N>-TP#Y@)%$3_L MD,$ $@#:MH2V.CS R5T"./!66X]9@B[VD/<-LY#07!HD6!6 $#F_NWAX>,AV M0X*"]LX");D=WSB,'I#>YLFW>1*>-0KJ!KE-O'Y#WIAOQMG@@V3SB MA,7J\=JI/8%5Q@RP8?=XVIKB]8K:*VNX$=? M+/U;RE=85>>:4ZE4"A(OR#CD9?>DH%D;=DL+6MJ P'=IT&VOQT3Y1MZ'!>N_ MNJCK!10/-@I\T'?IP?9-8]QS*?A28\.G7P4H/OU:E&!]^BW6:@V_ W\U!U>&(E &N2M,;<$L-"A1L M$O@LB_D4\A+YXHZ)^,@;!"&YN#_@TG $,F<$831I" /&B[#, 3E0O%./81\; MQUC41*CG\TJT@JQ<#@ 17OHV3(FXO.:MJ+<;3"F$#)U1;-?G!;IB,B=V!YR> MU&.\A8S(BJ$?P1\+I7).6RI^1V_*+1#J=+:^:=CF@%OG*:\A,#OIA'A.AT>1J*B89@&?/'P M3TD4%!.>'OA)36)P5JO80&FQ '+9BZ@8]-:[88UD4%+@K./CDYD#>S\M,!QV MOJQZXC,, B+H=_\,D+3\(770@J$[!'S%;A@.2C]705RPAFANT5)A+5D[M&1# M[1&00EV"%6:Q>O*]*)'MC'O%PO &Z_7 FP";15$R3-'X$W6/[8Z7!V(T7B"H MH;3GR1.LS[ D[%-"39%^_FK@J(IJN[/HAFZ*9Y^*-(VOZS"P-"FI&PCGXN41 M<4"FZGGS50OKE[O&N!@6E >>WQ="5,KF+@OE_4!YSHFGRS"13?N/TG0SBBD8 M4$,$[;<"R \/%H$^"1->A.)I7>U0W#1.M,E"P._ZIMU%&0'6V4.F'QY,"/\X MO53 CW+\D1@KR)5U->NGJ+AL8!>-1REPX*P>: )L:4?N?CH:C[B"D&_FCTW7 MT:A((G_5_M;$0]R+QOY?( C35G*VQ]E$$S/LX!=X?=SWG5AI'*X1YLOKV,Q- M= YYL\UZI^>:H*J9>%R$7VO40;0OQN"&Y+Y;:ST'BD:,+3MY)+J025:A5>0 M5R4^2M" !94V$![:J#?.53U0!\\?:"<^6VF/>/A :QC0?)'VT<+B=P5_0N! MQ3ZF\R%,P38Y/,_^W-H,71%0HMI/>!Q3_&ZX7'@X 1]$Y\*A9E .QU@80WW MLZ:N;H+KX?+Y[*X9>D((F0^_ZO"0/^(CO0RYE2%KR?)6^[R/\< M,(I9LVH2 T3\[EX@@:$7"_]"=.;H_A #?YUR,@H)A[K2JW7 MXRH7FT>RGT#0@6T;XL]"@:)E%GH36^>&FC-H083:TJ4>4IX''D$E[$5L2+;K MOT0^.)?F@]?3XR6IW5T*KYQ^]KA"6'8V9EF=/PF$KK7J;;/5^7;7)K7F=>=; MX[9ZT[CK-.MMY, '3=;I//M^JY=;5VV)=+X=[UQTR&MN^^UQBVY_@(056\;;0)_/3RX M@:_X[Z3Z_?JNU6E_VBBD=ZWJW643R/7IN7S#6@1S2[L&1#%[_J#_$J^*PT>O MVJZ<.<&UH&;UTL/.9]=L_?^UHK*U-)IV3-=,HK<4MG]/F3TC*>KEH")2(5;.T M![[6!40RXVU1//+(HC?]=U(HTB7U%NH5YM4[2,2BVI0I6MBSF%D8[O,C?GMF MI?*24II;7"I=4$O0KI"?6W7OW1?4AJS43$YLWH*[<>A(8\;D,N?XG,?X8)3( M%*Q.Q>7SC*_*+<8I9.N9,1#"HE0H+U]UX;U6S[YS"9;A*RJ^O[O^V(!!+H[& M95?B405;93J4$G:;F-M +#6\+U)/57*2O/NF]^CBJVT;>/!L+[BJJ)(:34ZF M2R(!Q$N8,4''$L\W!Y>Y,,?/XS@)BP?L#;NCS8K2M;(4\4I297Z[UW=?*FN- MV[!5A*=9?88)1.%K[<^"40M2N3*W-GBZ8%XF7GF=VB9QQN46L<;[$?PBU9XM ME)*4+ZTM2[SSM"L5]GK;:B:]$_243/-[;_/T)#G::#S-[R6,2Y5HB_']S.X] MMR4PE?+;*:T0.4JT5E%3U8I4*2W?^3%5"9MG44F65'FS6GN.1I@Z],DO0:ZK M251Q\6V-9YYZ8<253L5&WEOV4.P;)MQJI-9H1U:ZG2$@O&I6:\VK9J229< M<. MO[:+2LFUND<7+=O*I'F&W4$LZ9KZ>0]N/Y2-(JER>BMRU? HEX_L3N^^ MHEY0C,;&9@A]U-VZ;;G,"(IR[X4D*%*ILK9SUKM/.R69289-F:!+VJ,.[PJI M_9K8G_TYB MQOKHV"=AQVF'2.W(@+Q&K)S$I.I[_QA9M,8;C:=H'',?29N]Y MIUQZ/9!\WEI5PQX@FG:B$Y'%)+DBQOMHQ*GCE>D7JDB%:+G(!+ADVVP M7( _]$5S/8/VF,[VX[SQL5*H2&J\!_;WPZP?*W).4O.QUE/XM#W6Y\6SQM,K M*JB[80]'#AU0RV7WE)BVZY*/%O>-P'H[%"8);@GKC\1S-,N%E\&F$;V#J=?CR$ E"N1B\BQ'W9;>?&G+#K.Y:1\P'=)C7&UHXVH#TBY9&3J,P/MA952*@4IE[; M6)%Z:EZ5RI6]WM!ZT@V7$,ZY=$*(?/[ MU_E.E*TN+F.KDV+R M$VXU4HE5N3,V-W)5D^^WQ:^#$V;R$]%\Y4VTVWFO+!'-5S;E=HZ5Q4FG6KMJ MP&?\__E-",=0<_K,RGCVZ)3(9R3X-01+G@QVTIVFH4PP4 M9Q%_"^K/3C(>_A^9#/G"J&FH< MRG)3\KR< 0!/)"%@R 3Y\Q.8<\[T78=J/S-=B@GR4UC@"/,T2,4Y$"&8KYUR MBC G2!E!C/4S)-[A@^W\YO>OI'U;_WSD#=5<3@;=8"C_I;\JE8S"AGU95K)_ MCOI'I'K5^7RT(0GO69:/5;EP2^-2^OFI>5CL-U,OPXWNCU6F3ZR_D^@8 [#3A@<,#;/E3 MO_Y^<]OX!N\U?S3(U76[O4F0CYLMTOEV?=<&4-H2:?R[WKCID-;=]UKC%J'E M#8EX;Z+# P!<_$ZJWZ_O )U/&X7TKE6]NVP"0?FT<4V(&IU/G,V/PF,Q(4KB M;$PP#S=RI-ZXNKJI7EXV6U\_'\E'_/?V3;4>_CYK@\$S-K61"UHL_'1&'ICA M#1!.^9_+V^*CY=SRYP.SR(G YP[F\2\>*'H:HL/5:URM^C42I?7YJ'CTF@FB MG'_9RG0&#J5D"(,-7$(M@QI+)ZF>!V?G*-5BU@8(M70(.4=6'S""S+@C#7T3 MRWYPM%$$@$5L6>;=N'BE'KUYUE48V*8CCQ]L%M#E9$E\4.5HAXNY@,6\$O:; MY)&JN2G)4RG?.9)O4,K7O3,<.%[Y\BO\KKFAUI?K5F?&6/>T(3,?3U\:*F+) MKIB.?9J(0^^IY5.1JCC&*P+"\\2)+B(,"/S'5WF/SR7$5AAPJ=S7V-%=>>#G M+Q/$!/>"5;]W5"Y*2K189$KC6&E+0T?3T8''L%BD]LI3R*>53RJ>=Y=/ZKU+LTE%A=7)8)8CP4LE+ M-<1N\VEN%)ER*6%1=)%G'E=>"I.375LUDQXE7D4HI M[5;W4@KKN\6TZ\23YT5+.^K-O2)G\I5:X/>97)-KQI!9S/70#[Q/$RBK*[EB M9)6F(5_">'2LR%)967_Z)*U7LS*+U**DJFF#PZ2SZ5A1I4II_1IO-XJ7R5FU MP*QPK\)>*NF2RN%2<5E14M+2)HEGT[$BR9O3%BF'5MA7RDLE->TWGG0V*25) MJ6Q1=^&-'<0[OK)=]],)LW1[2$G/L8>AG;6MU+Z^07%OQL"FFGME%I7 L=WL M-F;*I1464C$G5=3U\RE=2*NG'L!)+6SVW$9RX]JCBVM>7SLPJ,=!J/HI;?63 M(I8BEOP# ANHS\FWDII!:=Y 4>S%MJ*RONK-NTXY25;3DP KNB=23D[E;E6Y M*Y7VNN+Z7)4=^'1[(0'':3>BUZ^:]-S1BL*FQDJY_9"VM=4XWPH_>M'I6O2K MX0>[7WV7>*ND0)E7<3=5.TO:N'B=Z_W0.ZI4B5==[Y'$*9)2>$,)\^WWJU\\ M:CN=14U3\ZL[5.G&27*YD]X=WPX^Y>3T@$_2>538["V"Q,9&RY^FG;M-F0K@ MZBY=KI(6+T@ZEW+1W%S*HX3QJ" 5E,T>U4RYM%+X7UY_>^PMCFO'9VM'CMUC M'A%]@T*+ZVF_4ME;.:Q5\E))B22^T]@V.2PJ285\>ATQZ5PZ+I2EO)(FB1+, M(C4OR;DM.EV[N6ZKVB^PJ18%VYI*UZK2-:=%=JJDD\:C4AH-)9U'*@85*9<2 MSZ5\>E%E#&>+>N38G+K^N1=;[Q [*DJL>^_[<=P#1# ][K%RF%64E$)ZDO;U M"KLHY7O$=@"7P3DN2HJ8$7%D" M5RK'N$6W;7L=K5;S!3!\>3E-^\5N.-#N;/%8I$),7 MBNE9L"U@U0)KF+(J>:Q2U:(D;_CF9G*CK%?L?8RH(ZQR9!=DUF@'&QYOC,B2 MF.W[L/&LK)S-O;A+E^9DWYE+GKW]?1R"ZQMV=Q( MGE6./8C>0PE-[?(V<"FUR]O"J=0N;P.7Y&RQLDUV>W,W,F91VXMKD?'2+,$W(M^CQ)HH$PYZ>>30 M ;5<=D])7V/6B=#9Y*/%2RP3++T&8Q'==QQJZ8_$/7%7)+*ZOH+ J:5I-Y@V2M2)9^R*,$L4J5<>L C\5PZSJM2*;>QA92X MF*@^8V[1T";/ZUI'%0]5D2I1MN^8N[J6DCN*5%(BN<*4<"\'2#FI5(GU5/J> M$$XI2FIT"^&]E?%[1$A199T6C5FW@Y!/3WXFG44;[A>3LNCU+%+DS?872'FT M H]>/E*1G)/3&SR8M835W<]:,9L_2P)16[FS[NAYO09#(Z/(C7P MIYS-(__.VW63P\/>HX]A-],S:,&""(X)_!4SW8(V'CXSZ&4]ZJWF$7)$* =X)EM9ALN MH3"K >"-/#KL4H?D9(FHLIHC=H]\:#&3#!E$Z+AA">]_D+/E\ L)YG-'5,=V M]^8C_AG >,.,*I^QF%5G9\R5)]_,3IF-BQ$R$+LV9G$M-@;CN.%0_\ADR!=& M3>.4W&A]6&=M^I=/+9V>D@+)9$+5<-G\$]?2?NV_OG(&ZJYG*R69$/Y+_U5J604-NS+LI+]<]0_(M6K MSN>C-O1MLY(U;AGKHWQ46Q#_Z]"*DHI4RS+F4(1 M+W#'Q]^["UT/R?XO$U!P=:8%&&1U>WA^4 M_)]MV=Y LX0;UK5]QXIQ=+#4'[4A! ,WMX3KKU@UXDQF,%YY8'-D4$L! A0#% @ 6X%I5\H[23+L" M&D !4 M ( !Y@, &)R;G,M,C R,S$Q,#E?9&5F+GAM;%!+ 0(4 Q0 ( M %N!:5=EU,KM!PP #>1 5 " 04- !B&UL4$L! A0#% @ M6X%I5^FO_[#M% 77 !( ( !M2$ '1M,C,S,#(W,&0Q M7SAK+FAT;5!+ 0(4 Q0 ( %N!:5?WAX(1AB< ,T" @ 6 M " =(V !T;3(S,S R-S!D,5]E>#DY+3$N:'1M4$L%!@ & 8 C $ ' (Q> $! end